\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes MissionsThe following calls for the Mission: Climate neutral and smart cities are now open:
| HORIZON-MISS-2024-CIT-01-01 | Rethinking urban spaces towards climate neutrality |
| HORIZON-MISS-2024-CIT-01-02 | Zero-pollution cities |
| HORIZON-MISS-2024-CIT-01-03 | Mobility Management Plans and Behavioural Change |
| HORIZON-MISS-2024-CIT-01-04 | Integrated peri-urban areas in the transition towards climate neutrality |
By clicking on the call topics, you will be directed to the EU Funding & Tenders Portal, where you can find more information.
Do not hesitate to contact your NCP if you have further questions or need assistance finding partners.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
AI Continent Deployment: Best use of technologies
The European Commission has published the recording and presentations from its 18 December 2025 info session on the call topics Data Space for Manufacturing (DIGITAL-2026-DSM-AI-09-DS-MANUFACTUR-STEP) and European Digital Media Observatory hubs (DIGITAL-2026-BESTUSE-TECH-EDMO-09-HUBS). The slides and recording are available on ... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
